Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy
Completed
- Conditions
- Growth Hormone Deficiency in Children
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 321
- Registration Number
- NCT03672617
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
Phase 1
Completed
- Conditions
- Metabolism and Nutrition DisorderObesity
- Interventions
- Drug: NNC9204-1706Drug: Placebo (NNC9204-1706)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT03661879
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
Completed
- Conditions
- Haemophilia BHaemophilia A
- Interventions
- Other: No treatment given
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 563
- Registration Number
- NCT03660774
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Seattle, Washington, United States
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 333
- Registration Number
- NCT03648281
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 105
- Registration Number
- NCT03638778
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 215
- Registration Number
- NCT03631186
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (NNC0113-2023)Drug: NNC0113-2023
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT03617081
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Semaglutide, 0.25 mgDrug: Semaglutide, 0.5 mgDrug: Semaglutide, 1.0 mgDevice: DV3372Device: PDS290 pen-injector
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 54
- Registration Number
- NCT03611322
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (semaglutide)Drug: Semaglutide
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT03611582
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Olympia, Washington, United States
A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Semaglutide, 1.0 mg/mLDrug: Semaglutide, 0.5 mg/mLDrug: Semaglutide, 1.34 mg/mLDrug: Semaglutide, 2.0 mg/mLDevice: DV3372, 0.5 mg/mLDevice: DV3372, 1.0 mg/mLDevice: PDS290Device: NovoPen®4
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 68
- Registration Number
- NCT03598621
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
© Copyright 2025. All Rights Reserved by MedPath